



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Attorney Docket Nos. 71369.368 and PFI-016CIPDV)

In re Application of: Orlow et al. ) Examiner: To Be Assigned  
Serial No. 10/758,335 ) Group Art Unit: 1614  
Filing Date: January 15, 2004 )

For: METHODS AND COMPOSITIONS THAT AFFECT MELANOGENESIS

\*\*\*\*\*

**CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR §1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail addressed to:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below.

5/21/04  
Date

  
Sarah Farris

\*\*\*\*\*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**PRELIMINARY AMENDMENT**

Dear Sir:

Prior to issuance of a first Office Action on the merits, please amend the above-referenced application as follows:

**In the Specification:**

On page 17, please delete the paragraph at lines 1-3 and replace it with the following paragraph:

*Figure 18 is a graphic representation providing measurements of tyrosinase activity of extract from melan-a melanocytes incubated with U18666A. Control cells received no drug treatment, and test cells were treated with 300  $\mu$ M PTU, 10  $\mu$ M IBMX, or 2.5  $\mu$ M U18666A.*

On page 17, please delete the paragraph at lines 4-6.

On page 81, please delete the paragraph at lines 13-15 and replace it with the following paragraph:

*Results of the Western blot analysis show that the total amount of tyrosinase in the cell after exposure to U18666A is not significantly less than the control, untreated cell.*